通过NHS获得的减重药物Mounjaro通过NHS有限,在整个英格兰造成痛苦。 Limited access to weight-loss drug Mounjaro through NHS causes distress across England.

尽管英格兰从几个月前正式推出,但不到一半的英格兰人可以通过国民保健制度获得减重药物Mounjaro。 Less than half of England has access to the weight-loss drug Mounjaro through the NHS, despite its official roll-out starting months ago. 在42个委托机构中,只有18个已开始开药,只有9个机构有足够的资金来治疗至少70%的合格病人。 Only 18 out of 42 commissioning bodies have begun prescribing the drug, and just nine have enough funding to cover at least 70% of eligible patients. 专家警告说,这给护理委员会造成了困难和财政压力。 Experts warn this has caused distress and financial strain on care boards. 国民保健制度计划在12年内推出该药物,预期在头三年将有220 000名病人符合资格。 The NHS plans to roll out the drug over 12 years, with 220,000 patients expected to be eligible in the first three years.